Bapineuzumab (anti-Aβ monoclonal) failed primary endpoints in two Phase III trials in mild-moderate Alzheimer's. ARIA-E vasogenic edema rate was elevated in APOE4 carriers, foreshadowing the BBB-permeability / APOE4 axis later articulated by Montagne 2020.

Evidence span

Bapineuzumab (anti-Aβ monoclonal) failed primary endpoints in two Phase III trials in mild-moderate Alzheimer's. ARIA-E vasogenic edema rate was elevated in APOE4 carriers, foreshadowing the BBB-permeability / APOE4 axis later articulated by Montagne 2020.

From Stephen Salloway et al. 2014, New England Journal of Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, mild-moderate AD; bapineuzumab Phase III 301 (APOE4-) + 302 (APOE4+ carriers, n=1090). NCT00574132 / NCT00575055.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required